{
    "2021-03-03": [
        [
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）：甲磺酸贝福替尼胶囊药品注册申请获受理",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "甲磺酸贝福替尼胶囊",
                        "药品注册",
                        "申请受理"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "全国人大代表丁列明：资本对创新药的过度追捧或导致泡沫现象",
                "features": {
                    "keywords": [
                        "全国人大代表",
                        "丁列明",
                        "资本",
                        "创新药",
                        "过度追捧",
                        "泡沫现象"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业一治疗晚期实体瘤创新药获准临床试验",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "晚期实体瘤",
                        "创新药",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）：BPI-21668片用于治疗晚期实体瘤获批临试",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-21668片",
                        "晚期实体瘤",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：BPI-21668片获批药品临床试验",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-21668片",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "午间公告：长春高新子公司、贝达药业获批开展药物临床试验",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "长春高新",
                        "子公司",
                        "药物临床试验"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业PI3Kα抑制剂BPI-21668获批临床",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "PI3Kα抑制剂",
                        "BPI-21668",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}